Sterling Pharma Solutions has announced the expansion of its pilot plant facility is now operational at its UK site following a £6million investment last year.
The new cGMP facility increases the existing pilot plant’s capacity by 33%, enhancing the CDMO’s scale-up capabilities and adding greater flexibility to cater for small to mid-scale clinical supply and commercial batch production.
The investment included the addition of three new reactor trains at scales of 225L, 500L and 1,360L, which will help the company to meet growing market demand for smaller API batch sizes.
“We’ve experienced significant growth over the past few years and as demand rises, we have taken steps to bolster our offering,” Kevin Cook, CEO at Sterling Pharma Solutions said. “There are a number of increasingly complex products entering the drug pipeline, many of which are intended for smaller patient populations, so the ability to cater for smaller volumes will be essential as we move forward.”
The investment will also allow Sterling Pharma Solutions to handle potent compounds across a range of equipment scales, complementing the company’s existing offering.